Table 9.
The correlation between the expression level of the studied genes and clinicopathological features of hepatocellular carcinoma cases
| Reduced expression | Over expression | |||||
| Variable | ISGF3G | TNF-α | VISA* | CDK-7 | NOTCH4 | BAX |
| Total: 17 (%) | 13 (76) | 15 (88) | 14 (82) | 12 (70) | 11 (64) | 13 (76) |
| Age (Mean ± SD) (57 ± 10.2) |
||||||
| < 57 = 10(59) | 8(80) | 9(90) | 8(80) | 7(70) | 7 (70) | 8(80) |
| > 57 = 7(41) | 5(71) | 6(85) | 6(85) | 5(71) | 4 (57) | 5(71) |
| Gender | ||||||
| Male:13(76) | 10(77) | 12(92) | 11(85) | 10(77) | 9(69) | 11(85) |
| Female:4(24) | 3(75) | 3(75) | 3(75) | 2(50) | 2(50) | 2(50) |
| Tumor site | ||||||
| Rirht = 11(65) | 9(82) | 10(90) | 8(73) | 7(64) | 6(55) | 9(82) |
| Left = 6(35) | 4(66) | 5(83) | 6(100) | 5(83) | 5(83) | 4(66) |
| Tumor size | ||||||
| ≤ 8 = 12(70) | 10(83) | 10(83) | 11(91) | 9(75) | 8(66) | 9 (75) |
| > 8 = 5(30) | 3(60) | 5(100) | 3(60) | 3(60) | 5(100) | 4 (80) |
| Grade | ||||||
| I+II = 14(82) | 10(71) | 13(93) | 12(85) | 10(71) | 8(57) | 10(71) |
| III = 3(18) | 3(100) | 2(66) | 2(66) | 2(66) | 3(100) | 3(100) |
| Safety margin | ||||||
| Pos 4 (24) | 2(50) | 3(75) | 4(100) | 3(75) | 3(75) | 3(75) |
| Neg 13(76) | 11(85) | 12(92) | 10(77) | 9(69) | 8(61) | 10(77) |
| Invasion | ||||||
| Pos 9 (53) | 7(77) | 8(88) | 8(88) | 8(88) | 9(100) | 6(66) |
| Neg 8(47) | 6(75) | 7(87) | 6(75) | 4(50) | 2(25) | 7(87) |
| Cirrhosis | ||||||
| Present: 10(59) | 8(80) | 9(90) | 8(80) | 7(70) | 7(70) | 9(90) |
| Absent: 7(41) | 5(71) | 6(85) | 6(85) | 5(71) | 4(57) | 4(57) |
| CAH | ||||||
| Pos: 9 (53) | 7(77) | 8(88) | 7(77) | 6(66) | 6(66) | 8(88) |
| Neg: 8(47) | 6(75) | 7(87) | 7(87) | 6(75) | 5(63) | 5(63) |
*VISA (also known as MAVS, IPS-I or CARDIF)